Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2013 by NxStage Medical
Information provided by (Responsible Party):
NxStage Medical Identifier:
First received: April 24, 2008
Last updated: March 1, 2013
Last verified: March 2013

The purpose of this study is to determine whether or not nocturnal hemodialysis is equivalent to short daily hemodialysis on a per treatment basis, using the NxStage System One in the home setting.

Condition Intervention
Kidney Failure, Chronic
End Stage Renal Disease, Requiring Dialysis
Device: NxStage System One

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™

Resource links provided by NLM:

Further study details as provided by NxStage Medical:

Estimated Enrollment: 58
Study Start Date: April 2008
Estimated Study Completion Date: July 2013
Estimated Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Intervention Details:
    Device: NxStage System One
    Comparison of Nocturnal (NHD) and Short Daily Hemodialysis (DHD) with the NxStage System One
Detailed Description:

End Stage Renal Disease (ESRD) continues to be a devastating clinical condition. The number of patients in 2004 affected by ESRD in the United States rose to 472,000. More than 104,000 new patients began therapy for ESRD in 2004 (1.5% greater than in 2003), while the prevalent dialysis population reached nearly 336,000 (3.4% higher). Total Medicare costs for ESRD in 2004 rose to $20.1 billion while non-Medicare costs rose to $12.4 Billion(1).

Treatment options for ESRD patients are currently limited to either transplantation or dialysis. As daily hemodialysis (DHD) continues to gain widespread acceptance in the dialysis community, there is also renewed interest in nocturnal hemodialysis (NHD) therapy.

NHD has the potential to provide certain advantages over both DHD and conventional thrice-weekly in-center HD. NHD typically consists of 6 - 10 hour treatments while the patient sleeps, providing more gentle fluid removal, more time for equilibration, improved hemodynamic stability and superior clearance of larger solutes(2).

The proposed study plans to explore whether or not NHD is equivalent to DHD on a per treatment basis, using the NxStage System One in the home setting.

  1. USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, NIH, NIDDK, Bethesda, MD, 2006
  2. Lacson E, Diaz-Buxo J: Daily and Nocturnal Hemodialysis: How do they stack up? American Journal Kidney Disease, Vol 38(2) Aug 2001: 225-239.

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have a stable prescription in the short daily home environment using the NxStage System One prior to enrollment.

Exclusion Criteria:

  • Patients are not eligible if:

    • they are currently enrolled in another drug or device study which could impact the successful completion of this study
    • they are currently on NHD, or less than 3 months since discontinuing NHD
    • if they were previously enrolled in this study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00667511

United States, California
Satellite Healthcare/Wellbound Recruiting
San Jose, California, United States, 95128
Contact: Jugjeet Atwal    408-309-5847      
Principal Investigator: Brigitte Schiller-Moran, MD         
United States, Illinois
Circle Medical Management Completed
Chicago, Illinois, United States, 60607
United States, Indiana
Indiana University Dialysis Center Completed
Indianapolis, Indiana, United States, 46202
United States, Kansas
Kansas Nephrology Research Institute, LLC Recruiting
Wichita, Kansas, United States, 67214
Contact: Paula Pond    316-262-2045   
Principal Investigator: Dennis Ross, MD         
United States, Missouri
Barnes Jewish Dialysis Center Recruiting
St. Louis, Missouri, United States, 63110
Contact: Brent Miller, MD    314-286-0801      
Principal Investigator: Judy Jang, MD         
Sub-Investigator: Brent Miller, MD         
United States, Nebraska
Dialysis Center of Lincoln Completed
Lincoln, Nebraska, United States, 68512
United States, New York
Rubin Dialysis Completed
Saratoga Springs, New York, United States, 12866
United States, Texas
DaVita Grapevine at Home Not yet recruiting
Grapevine, Texas, United States, 76051
Contact: Patricia Jevec    817-424-4091   
Principal Investigator: Michael Aragon, MD         
United States, Wisconsin
DaVita Bluemound Home Dialysis Recruiting
Wauwatosa, Wisconsin, United States, 53226
Contact: Gail Scott    414-755-6330   
Principal Investigator: William Elliott, MD         
Sponsors and Collaborators
NxStage Medical
Study Director: Paul Kravitz NxStage Medical
  More Information

No publications provided

Responsible Party: NxStage Medical Identifier: NCT00667511     History of Changes
Other Study ID Numbers: CP0010
Study First Received: April 24, 2008
Last Updated: March 1, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by NxStage Medical:
End Stage Renal Disease
Daily Hemodialysis
Nocturnal Hemodialysis
Kidney Failure
Kidney Disease

Additional relevant MeSH terms:
Kidney Diseases
Kidney Failure, Chronic
Renal Insufficiency
Renal Insufficiency, Chronic
Urologic Diseases processed this record on November 25, 2014